Kornimate/medical-research-clean huggingface dataset:
the effect of bulk filling flowable composite on caries recurrence in deep marginal elevation: a randomized clinical trial

Conditions: DME; Dental Caries; Dental; Deep Margin Elevation

Summary: deep marginal elevation usinge a bioactive dental material in deep subgingival class ii restorations, s-prg filler-containing materials offer significant benefits due to their bioactive properties, their ability to release fluoride, remineralization potential and acid neutralization, reducing the risk of recurrent caries, particularly at the gingival margin(imazato et al. 2023). the antibacterial and antifungal effects help inhibit biofilm formation, enhancing the longevity of restorations. additionally, these materials support better marginal adaptation by reducing microleakage and improving bond durability (imazato et al. 2023) this type of composite may improve the outcomes of deep subgingival margin elevation, benefiting both restorative success and periodontal health(imazato et al. 2023).


Eligibility criteria:
inclusion criteria: * adults patients (20-50) * good oral hygiene (plaque index 0 or 1 ) * patient approving to participate in the study * absence of parafunctional habits and/or bruxism * no sign of irreversible pulpitis * no periapical radiolucency * deep subgingival margin * molars class ii with subgingival margin exclusion criteria: * • patients with known allergic or adverse reaction to the tested materials. * systematic disease that may affect participation. * xerostomic patients. * bad oral hygiene (plaque index 2 or 3 ) * heavy smokers * patients undergoing or will start orthodontic treatment * patients with removable prothesis

Keywords: deep margin elevation
bone height and extractions study

Conditions: Alveolar Bone Loss; Periodontal Attachment Loss; Periodontal Pocket

Summary: a coronectomy is often chosen over complete extraction of a lower third molar when the tooth appears to be in close proximity to the inferior dental (id) canal, as assessed on a plain radiograph or a cone beam computer tomograph (cbct). following a coronectomy, the roots of the third molar may migrate in a coronal direction. this effect, along with the bone-preserving technique of a coronectomy over extraction, may provide increased bone height distal to the lower second molars, when compared to extraction. partially erupted lower third molars, specifically those with mesio-angular impactions, are commonly associated with reduced bone height distal to lower second molars, and cause damage to the periodontal support of these neighboring teeth. it is assumed that maintenance of the impacted third molars or extraction of these teeth may compromise the periodontal status of the lower second molars. this study will investigate if coronectomy improves the bone levels, and therefore the periodontal status, of lower second molars, and may propose an indication for a coronectomy regardless of the proximity of the tooth to the id canal. coronectomies were first proposed as a treatment option just over thirty years ago, but there are very few long-term studies on the procedure reported in the literature. to the best of the investigator's knowledge, this will be the first randomised controlled trial comparing the bone height distal to the lower second molar following a coronectomy or extraction of the lower third molar.


Eligibility criteria:
inclusion criteria: * patients requiring extraction of both lower third molars * both lower third molars to have mesio-angular impa * ctions, as assessed by location of the contact point between the crown of the third molar and the cemento-enamel junction (cej) of the second molar and the angulation of the third molar * both lower third molars must lie above or clear of the id canal as assessed on a plain radiograph or cbct * presence of lower second molars * patients must be ≥18yrs old * patients willing to attend follow up appointments exclusion criteria: * lower third molars with caries, periapical pathology or associated lesions such as cysts * patients who are immunocompromised, have a history of or due to have head and neck radiotherapy, chemotherapy, have previously been given or due to start intravenous bisphosphonates * smokers (\>5 cigarettes/day) * patients involved in current research or have recently been involved with research prior to recruitment
a study on switching from daily dpp-4 inhibitor to hsk7653 in type 2 diabetes patients

Conditions: Type 2 Diabetes

Summary: to assess the effectiveness of hsk7653 tablets following the substitution of daily dpp-4 inhibitor (dpp-4i) over a 24-week treatment period.


Eligibility criteria:
inclusion criteria: * age ≥18 and age ≤75 years * t2dm patients, * during the 12 weeks before screening, on the basis of diet control and exercise therapy, patients only regularly received daily dpp-4 inhibitors (such as sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin and retagliptin , etc.) or combined with metformin (with a metformin dose of ≥ 1500 mg/day, or the maximum tolerated dose \< 1500 mg/day but ≥ 1000 mg/day); * hba1c ≥6.5% and hba1c \<8.0% * fpg \<10.0 mmol/l * bmi ≥19 and bmi ≤ 35 kg/m2 (body mass index) exclusion criteria: * non-type 2 diabetes: type 1 diabetes, gestational diabetes or other special types of diabetes. * the presence of any of the following medical histories or conditions at the time of screening: * history of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the recent 6 months; * history of ≥2 episodes of severe hypoglycemia within the last 6 months; * history of malignant tumors within the recent 5 years (except for cured basal cell carcinoma of the skin and cervical carcinoma in situ), or currently being evaluated for potential malignant tumors. * presence of severe mental disorders or language barriers, unwilling or unable to fully understand and cooperate. * history of drug abuse within the past 5 years * previous history or clinical evidence of acute or chronic pancreatitis. * using other drugs that may affect blood glucose metabolism within 12 weeks prior to screening, including systemic glucocorticoids (except for inhaled or topical ones), growth hormones, etc. * any laboratory test index meeting the following criteria: * hemoglobin \< 110 g/l (for males) or \< 100 g/l (for females). * alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) \> 3 times the upper limit of the normal value. * total bilirubin (tbil) \> 2 times the upper limit of the normal value. * fasting triglyceride (tg) \> 5.7 mmol/l. * estimated glomerular filtration rate (egfr) calculated using the ckd-epi formula \< 45 ml/min/1.73m². * known to be allergic to the investigational products or related excipients.

Keywords: hsk7653 dpp-4i
cardiovascular diseases in hiv-infected patients hiv-heart study: 7.5 years follow-up

Conditions: Coronary Heart Disease; Heart Failure; HIV; AIDS; Metabolic Syndrome

Summary: since the introduction of antiretroviral therapy life expectancy of hiv-infected persons is rising. different cohorts are observing an increased risk for cardiovascular diseases in this aging hiv-infected population. traditional cardiovascular risk factors like smoking are more frequent in hiv-infected persons. for example chronic inflammation due to hiv-infection and metabolic disorders also caused by some antiretroviral substances as special non-traditional risk factors in hiv-infected persons can influence the development of cardiovascular diseases additionally. therefore new research focus in special risk profile associated with hiv-infection or antiretroviral treatment and prevention for hiv-infected patients is developing. this present study is an ongoing prospective regional multicenter trial that was conducted to analyse the incidence, prevalence and clinical course of cardiovacular disorders in hiv-infected out-patients. cardiac disorders witch are associated with hiv are pericarditis, pleural effusion, pulmonary hypertension, dilated cardiomyopathy, heart failure, myocarditis, bacterial endocarditis and heart valve disorders. in addition to previously stated disorders of the heart, the premature atherosclerosis of coronary arteries, a further even more important disease of the heart in this patient population, went into the focus of most hiv-researchers and physicians.

a comprehensive detailed description of the study procedures had been previously published (european journal of medical research 2007;12:243-248).

Eligibility criteria:
inclusion criteria: * age \> 18 years * known hiv-infection * written informed consent exclusion criteria: * acute cardiovascular disease * unstable hemodynamic status in the three weeks before inclusion * pregnancy

Keywords: cardiac diseases hiv-infection aids antiretroviral therapy cardiovascular medication risk factors coronary heart disease heart failure metabolic syndrome
minor traumatic brain injury : mri examination of consequences and social insertion

Conditions: Traumatic Brain Injury

Summary: minor traumatic brain injury (mtbi) (glasgow coma scale 13 to 15) represent 70 to 90% of traumatic brain injury. different disorders may occur after a traumatic minor brain injury (somatic, cognitive or affective) within 2 weeks. for 10 to 20% these symptoms are persistent and are part of post-concussion syndrome. today a small amount of tools to predict this syndrome are available. cerebral ct scan, a routine test for mtbi, isn't relevant to predict the post concussion syndrome. in order to improve understanding of the evolution toward this complication, it seems relevant to run a multimodal study. multiparameter mri combined to psychological and sociological evaluations cold provide a better global perception.


Eligibility criteria:
inclusion criteria: * patients who answered to psychological questionnaires 3 month after mtbi * patients with mtbi according to european federation of neurological societies * initial ct scan indication according to 2012 french society of emergency medicine and european federation of neurological societies * health insurance * written consent exclusion criteria: * under 18 years * psychiatric or neurologic history with long term treatment * hospitalization due to extra-cranial wounds or intoxication (except alcool) * mtbi due to aggression * mri contraindication * inability to understand french language * pregnant or breastfeeding women * incapacitated patients in accordance with article l 1121-5 to l1121-8 of the public health code * patients in another study's exclusion time * inability to have a follow-up * patients who can't be reached in case of emergency
evaluation of the efficacy of duodenal prostheses not covered over 6 years

Conditions: Digestive or Non-digestive Neoplasia Leading to Symptomatic Duodenal Stenosis

Summary: to assess the efficacy of duodenal prostheses for duodenal stenosis established for endoscopic pyloric or duodenal stenosis on dysphagia

duodenal prostheses have become, since the 2000s, the first-line treatment of unresectable duodenal tumoral stenosis. the technical success is greater than 90%, however the endoscopic revisions that are duodenal or biliary are frequent. the ipc as a center of interventional endoscopy is very often in charge of these stenoses. we wanted to evaluate the efficiency and the duration of this effectiveness in current situation. is there still room for gastrojejunal gastrojejunal surgery or for the development of endoscopic gastrojejunal anastomoses?

Eligibility criteria:
inclusion criteria: * any symptomatic duodenal stenosis with symptomatic duodenal duodenal prosthesis between 2010 and 2017. exclusion criteria: * benign stenosis or covered metallic duodenal prosthesis (usually indicated for benign disease)

Keywords: duodenal stenosis pyloric stenosis digestive neoplasias non-digestive neoplasias duodenal prosthesis
infantile hemangioma with minimal or arrested growth : epidemiology, clinical characteristics and evolution

Conditions: Hemangioma, Capillary

Summary: infantile hemangioma (ih) is the most common vascular tumor of infancy, characterized by its clinical history. absent at birth or present under the form of a premonitory mark, they display a rapid proliferative phase starting in the first weeks of life. then, after a plateau phase, they slowly involute. however, a subtype of ih named "abortive", "minimal or arrested growth", "reticular" or "telangiectatic" hemangioma differs from typical ih because it doesn't have a proliferative component, or only a minimal one. this subtype of hemangioma has been recently described and data are lacking regarding its proportion among infantile hemangioma and its differences with "classic" infantile hemangioma. the aim of this study is to estimate the proportion of abortive hemangioma among infantile hemangioma. also, the investigators aim to compare the clinical characteristics of "classic" infantile hemangiomas and abortive hemangiomas. lastly, investigators wished to study the evolution of abortive hemangioma.


Eligibility criteria:
inclusion criteria: * children between 0 and 18 years old * followed in the dermatology department of chru de nancy between january 2014 and december 2020 * presenting with one or more infantile hemangioma exclusion criteria: - those whoes guardian does not want his data to be collected in this study
survey on long-term use of orencia® intravenous infusion 250mg

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study to collect information on the safety, especially serious infections and malignancies, and efficacy of the long-term use of orencia intravenous infusion 250mg in patients with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * patients who are beginning to receive the treatment with orencia intravenous infusion 250mg under the approved indications, dosage, and administration * have available haq data * have available das28-esr or das28- crp data * have no past or present history of malignancies * are expected to be followed up for 3 years
effects of psilocybin in anorexia nervosa

Conditions: Anorexia Nervosa

Summary: this open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (an). psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. the investigators seek to determine whether similar changes can be safely produced in people with an when psilocybin is administered in a supportive setting with close follow-up. the investigators' primary hypotheses are that psilocybin is safe to administer in people with an, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life. the investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.


Eligibility criteria:
general inclusion criteria: * currently meet criteria for an restricting subtype by diagnostic and statistical manual 5th edition (dsm-5) criteria, and have a history of an for at least 3 years prior to screening * have at least one prior attempt at treatment * be otherwise medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ecg), and routine medical blood and urinalysis laboratory tests (complete blood count, comprehensive metabolic panel, urine pregnancy test, urine toxicology screen). * agree to refrain from using any psychoactive drugs, including alcoholic beverages and nicotine, within 24 hours of each drug administration. the exception is caffeine. general exclusion criteria: * women who are pregnant (as indicated by a positive urine pregnancy test assessed at intake and before each drug session) or nursing; women who are of childbearing potential and sexually active who are not practicing an effective means of birth control. * cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant ecg abnormality, heart valve, or transient ischemic attack in the past year. resting heart rate may be no less than 50 beats per minute unless cleared by a cardiologist. * epilepsy with history of seizures * type 1 diabetes * first degree relative with schizophrenia spectrum or other psychotic disorders (except substance/medication-induced or due to another medical condition), or bipolar i disorder * has a psychiatric condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin
pain control in patients with recurrent or metastatic breast or prostate cancer

Conditions: Breast Cancer; Pain; Prostate Cancer

Summary: rationale: an outpatient educational and behavioral skills training program may help patients with metastatic breast or prostate cancer live longer and more comfortably. purpose: this randomized clinical trial studies whether an outpatient educational and behavioral skills training program will improve pain control in patients who have metastatic or recurrent breast or prostate cancer.

objectives: * evaluate the feasibility of implementing an outpatient education and behavioral skills training program for pain control in a multi-institution setting. * evaluate whether patient education and behavioral skills training improve cancer pain control in patients with recurrent or metastatic breast or prostate cancer. * amend the protocol, with the approval of the division of cancer prevention and control, to a groupwide 3-arm study if analysis demonstrates feasibility and potential efficacy of the patient education and behavioral skills training program. outline: this is a randomized study. patients are stratified according to diagnosis (breast vs prostate cancer), initial "pain worst" score (4-6 vs 7 or higher), and participating institution. patients are randomized to 1 of 2 treatment arms. * arm i: patients receive standard pain management. * arm ii: patients receive educational intervention (booklets, audiotapes, and videotapes) and behavioral skills training (including a schedule of practice relaxation sessions) in addition to standard pain management. patients receive a follow-up phone call within 48-72 hours of intervention to review pain status. patients on both arms undergo pain and psychological assessments on days 1 and 15. projected accrual: a total of 96 patients (48 per arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: * recurrent or metastatic breast or prostate cancer * "pain worst" score of 4 or greater on the brief pain inventory * no prior enrollment on this study (patients treated during the run-in period are ineligible for randomization) * hormone receptor status: * not specified patient characteristics: age: * 18 and over menopausal status: * not specified performance status: * ecog 0-2 hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no major psychiatric illness, including the following dsm-iii-r diagnoses: * bipolar disorder * schizophrenia * major depression * multiple personality disorder * psychotic disorder * dementia * outpatient status required prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * not specified radiotherapy: * at least 28 days since prior palliative radiotherapy to major site(s) of pain surgery: * greater than 30 days since prior surgery

Keywords: stage iv breast cancer recurrent breast cancer stage iv prostate cancer recurrent prostate cancer pain
a study comparing ibi362 vs semaglutide in chinese adults with early type 2 diabetes and obesity

Conditions: Type 2 Diabetes; Obesity

Summary: this is a multicenter, randomized, open-label phase 3 clinical study comparing the efficacy and safety of ibi362 6 mg ow versus semalgutide 1 mg ow in obese(bmi≥28kg/m2) early t2d subjects. subjects will be randomly assigned to ibi362 6 mg and semalgutide 1 mg groups. all study treatment will be administered once-weekly and subcutaneously. the entire trial cycle includes a 2-week screening period, a 40-week double-blind treatment period, and a 4-week drug withdrawal safety follow-up period


Eligibility criteria:
inclusion criteria: * male or female, age 18 years or older at the time of signing informed consent * t2d was diagnosed according to who standards in 1999(≤5 years) * the blood glucose was not well controlled after diet and exercise with/without sable metformin(≥1500mg/day，no more than 2550mg/day) within 3 months before screening, and the local laboratory tested 7.5% ≤ hba1c ≤9.5% during screening * have a bmi ≥28 kg/m2 exclusion criteria: * subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs * a self-reported change in body weight above 5% within 3 months before screening * oral hypoglycemic drugs other metformin have been used within 2 months before screening. * previous diagnosis of type 1 diabetes (including adult latent autoimmune diabetes) * there are active or untreated malignant tumors within 5 years before screening, or patients are in remission of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery) * mental illness existed in the past or at the time of screening, and the researcher thinks it is not suitable to participate in this study * pregnant or lactating women, or men or women who are fertile and unwilling to use contraception throughout the study period * the investigator believes that the subject has any other factors that may affect the efficacy or safety evaluation of this study and is not suitable to participate in this study